Literature DB >> 1878411

N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination.

S Garg1, P K Garg, M R Zalutsky.   

Abstract

N-Succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates (alkyl = Me, Bu) have been prepared and used as a precursor to label N-succinimidyl 5-[131I]iodo-3-pyridinecarboxylate (SIPC). SIPC was obtained in greater than 80% yield from either the methyl or butyl precursor with N-chlorosuccinimide and heating at 60-65 degrees C. Significantly lower yields were observed with tert-butyl hydroperoxide. After a 30-min incubation with [131I]SIPC at pH 8.5, goat IgG, an intact monoclonal antibody (MAb), and a MAb F(ab')2 fragment were labeled in 60-65% yield. Specific binding of the MAb and MAb fragment after SIPC labeling was identical with that observed with N-succinimidyl 3-iodobenzoate and higher than that reported previously for these MAbs after labeling by using the Iodogen method. When 5-[131I]iodonicotinic acid was injected into normal mice, thyroid uptake was less than 0.2% of the injected dose, reflecting the inertness of this compound to deiodination. Paired-label biodistribution studies indicate that for both the MAb and the F(ab')2 labeled by using SIPC, accumulation of activity in the thyroid and other tissues is comparable to that observed when these proteins were labeled by using N-succinimidyl 3-iodobenzoate. The results of this study suggest that SIPC may be a reagent for labeling MAbs with halogen nuclides.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1878411     DOI: 10.1021/bc00007a009

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  9 in total

1.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.

Authors:  Ying Chen; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Mrudula Pullambhatla; James J Fox; Mark Castanares; Shawn E Lupold; John W Babich; Ronnie C Mease; Martin G Pomper
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

2.  Targeting aldehyde dehydrogenase: a potential approach for cell labeling.

Authors:  Ganesan Vaidyanathan; Haijing Song; Donna Affleck; Darryl L McDougald; Robert W Storms; Michael R Zalutsky; Bennett B Chin
Journal:  Nucl Med Biol       Date:  2009-10-03       Impact factor: 2.408

Review 3.  Radiopharmaceutical development of radiolabelled peptides.

Authors:  Melpomeni Fani; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

4.  Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios.

Authors:  Zhengyuan Zhou; Darryl McDougald; Nick Devoogdt; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  Mol Pharm       Date:  2018-11-28       Impact factor: 4.939

5.  Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents.

Authors:  Alla Darwish; Megan Blacker; Nancy Janzen; Stephanie M Rathmann; Shannon Czorny; Shawn M Hillier; John L Joyal; John W Babich; John F Valliant
Journal:  ACS Med Chem Lett       Date:  2012-02-18       Impact factor: 4.345

6.  D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.

Authors:  Marek Pruszynski; Eftychia Koumarianou; Ganesan Vaidyanathan; Satish Chitneni; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-08-13       Impact factor: 2.408

7.  Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative.

Authors:  Zhengyuan Zhou; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  Bioorg Med Chem       Date:  2020-07-09       Impact factor: 3.641

8.  N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization.

Authors:  Jaeyeon Choi; Ganesan Vaidyanathan; Eftychia Koumarianou; Darryl McDougald; Marek Pruszynski; Takuya Osada; Tony Lahoutte; H Kim Lyerly; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-08-01       Impact factor: 2.408

9.  Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy.

Authors:  Eun Jung Kim; Byoung Soo Kim; Dan Bee Choi; Sung-Gil Chi; Tae Hyun Choi
Journal:  Oncol Rep       Date:  2016-03-24       Impact factor: 3.906

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.